Clinical Trial

A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and activity of RO7790121 in participants with advanced metabolic dysfunction-associated steatohepatitis (MASH) fibrosis.
Protocol Amendment History 2 changes
notable Primary completion moved earlier: 2026-12-30 -> 2026-09-30 2026-04-17
notable Trial sites reduced: 24 -> 15 locations 2026-04-08
Trial Details
NCT Number NCT06903065
Lead Sponsor Hoffmann-La Roche
Conditions MASH
Enrollment 50 participants
Start Date 2025-04-14
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-15